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Abstract Growth may be severely impaired in children
with chronic renal insufficiency. Since short stature can
have major consequences on quality of life and self-esteem,
achieving a ‘normal’ height is a crucial issue for renal
transplant recipients. However, despite successful renal
transplantation, the final height attained by most recipients
is not the calculated target height. Catch-up growth spurts
post-transplantation are usually insufficient to compensate
for the retardation in growth that has occurred during the pre-
transplant period. Longitudinal growth post-transplantation is
therefore influenced by the age at transplantation but also by
subsequent allograft function and steroid exposure, both of
which interfere with the growth hormone/insulin-like growth
factor axis. The management of growth retardation in renal
transplant recipients includes adequate nutritional intake,
correction of metabolic acidosis, prevention of bone disease,
steroid-sparing strategies and a supraphysiological dose of
recombinant human growth hormone in selected cases.
Keywords Children.Corticosteroids.Growth.
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Introduction
One of the goals of renal transplantation in children is to
restore an optimal quality of life (QOL), including the
optimization of final height. However, catch-up growth
post-transplantation is generally not sufficient to compen-
sate for the deficit that has been acquired during the pre-
transplant period. Growth retardation post-transplantation is
multifactorial and associated with impaired medical and
psychosocial outcomes. Despite numerous recent develop-
ments in pediatric renal transplantation, achieving an
adequate final height remains a challenging issue for such
recipients.
Growth assessment
Growth assessment and management should be performed
in any pediatric transplant recipient [1]. Anthropometric
parameters, including height, body weight, body mass
index (plus head circumference in children less than 3 years
of age), should be monitored every 3 months in children
less than 3 years of age, then every 6 months until final
height is reached. Final height is reached as the growth
velocity per year minus 1–2 cm after puberty has occurred.
The target height (H, in cm) is based on mid-parental height
(girls = [Hmother +H father–13]/2; boys = [Hmother +H father +
13]/2) according to Tanner method [2]. A more recent
formula based on parental height standard deviation score
(SDS) and independent of sex has been proposed [3].
Growth parameters should be plotted on growth charts
using either SDS or centiles adapted to gender and local
standard measurements.
Growth features post-transplantation
Magnitude of growth impairment post-transplantation
Data from the North American Pediatric Renal Trials
and Collaborative Studies (NAPRTCS) 2006 annual
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cohort of over 1500 patients aged 19 years or more [4],
with 25% of these patients having a height SDS of −2.3 or
worse and 10% being below −3 . 3S D S .D u r i n gt h el a s t
10 years, single center reports have specifically addressed
the issue of final height after renal transplantation in
childhood [5–10]. The percentage of patients who
achieved a normal final height (height SDS ≥− 1.88, i.e.
third centile) ranged from 42 to 75% (Table 1)w h i c hi s
higher than the that reported in previous studies in which
62–77% of patients exhibited growth failure at 18 years of
a g eo rm o r e[ 11, 12].
Impact of growth failure post-transplantation
Growth delay post-transplantation may be associated with
a worse medical outcome. Furth et al. [13] showed that
children with end stage renal disease (ESRD) and moderate
(−2 > SDS > −3) or severe (< −3 SDS) growth retardation
had a significantly higher risk of death and hospitalization,
even after adjustment for treatment modalities (dialysis or
transplant). Such events were mainly attributed to infectious
diseases, suggesting that growth failure might be a marker
of poor nutritional status, a known risk factor for infectious
complications.
Growth failure may also have an impact on psycho-
logical and social development, self-esteem and QOL.
Behavioral and cognitive disorders, including immaturi-
ty, inhibition, anxiety, attention deficits and learning
d i s a b i l i t y ,h a v eb e e nr e p o r t e di nc h i l d r e nw i t hs h o r t
stature [14, 15]. Such difficulties were attributed to family
overprotection and negative social experience related to
the child’s short stature, leading to impaired emotional and
social development. Experience in patients with growth
hormone deficiency or idiopathic short stature has shown
that the use of recombinant human growth hormone
(rhGH) improves behavior disturbances [16]. In adults
who were transplanted during childhood, short stature has
been associated with a lower marital status, a lower level
of education and a lower level of employment [17].
Moreover, Rosenkranz et al. reported that more than one-
third of adults with childhood-onset ESRD were dissatis-
fied with their body height [18]. Positive perception of
QOL significantly correlated with satisfaction with adult
height.
Factors influencing growth post-transplantation
Growth after transplantation is mainly affected by the
degree of pre-transplantation growth deficit, age at trans-
plantation, graft function and exposure to glucocorticoids.
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Growth failure is a common feature in children with
chronic renal insufficiency (CRI). Growth determinants
during the pre-transplant period may include age at
diagnosis of CRI, nutritional intake, primary disease,
tubular impairment, renal osteodystrophy, hormonal disor-
ders and pre-transplantation use of steroids. Two periods
are at particular risk of impaired growth velocity: infancy
and puberty [19, 20]. Height velocity generally decreases
when the glomerular filtration rate (GFR) is below 30 mL/min
per 1.73 m
2 [21]. However, there is evidence that growth
impairment begins earlier. Indeed, in a subset of the
NAPRTCS registry [4] that includes 1901 patients with
moderate CRI (estimated GFR between 50 and 75 mL/min
per 1.73 m
2), 21.5% had standardized height measurement
below the third centile (height SDS ≤−1.88) and in 2477
children with an estimated GFR of 25–50 mL/min per
1.73 m
2, 36.8% had a height SDS of less than −1.88.
Children enrolled in this registry are growth impaired at
initiation of dialysis and exhibit a deceleration of growth
during the following 6, 12 or 24 months—with the exception
of children aged 0–1 years. At the time of transplantation, the
mean height SDS measured in 8659 children was −1.86 for
boys and −1.72 for girls [4].
Pre-transplantation growth impairment may be reduced
by adequate conservative treatment of CRI, including
aggressive nutritional support during infancy and early
childhood [22] and treatment with rhGH when indicated
[23]. This has resulted in a significant improvement of pre-
transplantation growth; data from the NAPRTCS [4] has
shown that height SDS at the time of initial transplant has
improved from a mean of −2.4 in 1987 to −1.5 in the 2000
and 2003 cohorts.
Role of age at transplantation
IntheNAPRTCS2006report[4], only infants and pre-school
age children (2–5 years) exhibited catch-up growth post-
transplantation (Fig. 1). However catch-up growth occurred
mainly during the first 2 years post-transplantation, with no
further improvement being observed thereafter; preschool-
aged children who had the greatest deficit at transplant
(−2.26 SDS) exhibited the best growth improvement of 0.5
SDS. Conversely, school age children (6–12 years), and
adolescents demonstrated either no improvement or even a
decrease in height SDS (Fig. 1). The prepubertal growth
deceleration that occurs in the normal population is
prolonged after transplantation, and puberty and bone age
are usually delayed [8, 12]. This means that growth
continues for longer than normal but height gain is rarely
as much as expected due to loss of height potential [8, 24].
However, some authors have reported that significant catch-
up growth can occur after transplantation even in children of
pubertal age [25]; the authors speculated that catch-up
growth may be related to the early use of a low-dose and
alternate-day steroid regimen.
Effect of graft function
The effect of a reduced GFR on growth has been known for
a long time [26]. A report from the NAPRTCS that assessed
final adult height in 237 subjects who received a transplant
before 11 (girls) or 12 (boys) years of age showed that a
decreased GFR was an independent predictor of reduced
final height [27]. Guest et al. reported that prepubertal
children with a serum creatinine level above 120 μmol/L
did not exhibit catch-up growth during the first year post-
transplantation [28]. More recently, Nissel et al. showed
that prepubertal catch-up growth and total pubertal height
gain correlated positively with GFR [8].
Role of steroid therapy
Since the introduction of steroid therapy more than 50 years
ago, it became clear that daily and prolonged steroid admin-
istration leads to growth impairment [29]. Steroid therapy
inhibits growth by both interfering with the hypothalamus-
pituitary/growth hormone/insulin-like growth factor axis
and having a direct effect on bone formation (see below).
Pharmacokinetic studies of methylprednisolone in pediat-
ric liver and kidney transplant recipients have demon-
strated that the area under the serum concentration–time
curve (AUC) rather than dose was predictive for growth
retardation [30, 31]. However, this correlation between
AUC and growth was not unanimously found in trans-
planted children treated with prednisone or prednisolone
[32].
Fig. 1 Mean changes (±SE) from baseline in height standard
deviation score (SDS) by age at transplant (data from the NAPRTCS
2006 annual report)
Pediatr Nephrol (2009) 24:1297–1306 1299Other factors
Many other factors may contribute to post-transplant growth
retardation.
Donor type Pape et al. identified 51 boys who received a
renal transplant (30 deceased donors and 21 living related
donors) before the rhGH era, who were followed for at least
5 years [33]. Children who received a living donor graft
had a significantly greater height SDS and growth velocity
during the first 5 years post-transplantation than those who
received a graft from a deceased donor. Interestingly, this
difference remained significant after adjustment for poten-
tial confounders, including GFR. In the latest NAPRTCS
report, donor source seemed to predict height SDS changes
2 years post-transplantation, but the mean difference was
less than 0.3 SDS [2].
Pre-emptive transplantation As dialysis is associated with
decreased growth velocity, pre-emptive renal transplanta-
tion may optimize final height. Some authors reported
better height SDS in the first years post-transplantation in
those children who received a pre-emptive renal transplant
compared to those with dialysis prior to transplantation [6,
25].
Race A previous NAPRTCS report suggested that race may
also have an impact on growth following transplantation
[34]. The change in height SDS was negative in African-
American and Hispanic recipients but positive in Cauca-
sians. However, race did not significantly influence growth
in multivariate analysis.
Pathophysiology of growth impairment
post-transplantation
Disturbances in the growth hormone/insulin-like growth
factor axis
In humans, longitudinal bone growth is achieved primarily
by endochondral ossification, and an intact function of
the somatotropic hormone axis is essential for normal
growth. In healthy individuals, growth hormone (GH) is
secreted by the pituitary gland in a pulsatile pattern; such
a mechanism is regulated by GH releasing hormone
(GHRH), GH release inhibiting hormone (GHRIH) and
other feedback regulator agents. Growth hormone acts on
the liver and other tissues, where it stimulates the synthesis
of insulin-like growth factor-1 (IGF-1) and its binding
proteins (IGFBP). Circulating free IGF-1 stimulates the
proliferation of chondrocytes in the growth plate [35]. The
IGFBPs, in turn, modulate IGF-1 activity, mostly by an
inhibitory action mediated by IGFBP-3. Growth impair-
ment in renal transplant recipients is multifactorial, and the
somatotropic axis may be disturbed by several complex
mechanisms.
Glucocorticoids are known to interfere with the GH/
IGF axis by inducing down-regulation of GH receptors
and inhibition of IGF-1 synthesis [36] and by modifying
the equilibrium among IGFBP subtypes [37]. However,
exogenous GH may reverse the catabolic and growth-
depressing effects of glucocorticoids [38, 39]. In addition,
glucocorticoid treatment directly affects growth plate
function by suppressing chondrocyte proliferation, reducing
bone formation and altering endochondral ossification [40,
41].
Impaired renal function in transplant recipients per se
also contributes to growth disturbance so that even a
minimal graft dysfunction may be associated with growth
retardation [42]. Due to both decreased metabolic clearance
and altered release pattern, GH concentration is normal or
elevated in any child with CRI [43, 44] so that such patients
exhibit a resistance profile to GH action. Indeed, it has been
shown that uremia results in reduced GH receptor density
and in a defect of intracellular GH receptor signal
transduction, so that IGF-1 transcription is decreased [45].
Furthermore, modifications in IGFBPs levels limit the
bioavailability of free IGF-1 [46, 47].
Metabolic acidosis
The presence of metabolic acidosis may additionally
affect growth through a reduction of GH and IGF-1
secretion [48] as well as by GH resistance [49]. This
phenomenon is attributable to a down-regulation of hepatic
IGF-1 and GH receptor expression and increased expres-
sion of IGFBP-2 and -4, both of which inhibit the effects of
IGF-1 [50]. In addition, metabolic acidosis has been shown
to have an inhibitory effect on cartilage cell progression and
endochondral bone formation in experimental studies [51].
It also leads to reduced albumin synthesis, increased
calcium efflux from bone and protein degradation. Howev-
er, there is no evidence that a correction of metabolic
acidosis will have a beneficial effect on growth post-
transplantation.
Secondary hyperparathyroidism
Long-term secondary hyperparathyroidism may persist after
renaltransplantation[52] and have a negative impact on bone
turnover and growth plate function [48]; this may be
attributable to abnormal epiphyseal growth plate due to
reduced PTH/PTHrP (PTH-related peptide) receptor and type
X collagen expression. A potential benefit of treating for
1300 Pediatr Nephrol (2009) 24:1297–1306secondary hyperparathyroidism is an improvement in linear
growth, although there is no strong evidence supporting this.
Nutrition
Independently of the above mechanisms, proteinocaloric
deficit and subsequent malnutrition result in growth
retardation, mainly in infants and young children. Indeed,
protein restriction leads to a resistance to GH action at the
hepatic level, an increase in IGF-1 clearance rate and,
consequently, a reduction of IGF-1 levels [53–55].
Sex hormones
Disturbances of the gonadotropic axis may contribute to
altered growth patterns, with a delay and a shorter duration
in the pubertal growth spurt [8, 12, 56].
Management of growth post-transplantation
Conservative strategies
Growth velocity can be improved by conservative
approaches, including adequate nutritional intake, correc-
tion of metabolic disorders, prevention of renal osteodys-
trophy and steroid-sparing protocols (Table 2). The use of
alternate-day steroids in kidney transplantation was first
described in the 1970s [57], and several studies carried out
subsequently have demonstrated an improvement in growth
in patients on daily low or alternate-day steroid therapy [58,
59]. The use of deflazacort, a synthetic glucocorticoid
derived from prednisolone, has led to improved growth
velocity with a comparable immunosuppressive effect [60],
but there are few data on this drug because of its limited
availability. Encouraging results have been reported with
steroid avoidance or early withdrawal protocols [61–64],
but additional evidence is expected from ongoing trials.
Growth hormone therapy
Efficacy and safety
The rationales for the use of rhGH in short children with
renal transplants are: (1) exogenous GH can be considered
to be a substitutive therapy in children with glucocorticoid-
induced GH hyposecretion and (2) rhGH may restore IGF
bioactivity in those with normal GH secretion but decreased
IGF bioavailability [65, 66]. Four randomized controlled
trials have been conducted to evaluate the safety and
efficacy of rhGH after renal transplantation [67–70]. All
four studies have shown a significant improvement in
growth velocity in the treated group compared to the
controls (Table 3), but none of these trials has remained
controlled for more than 1 year. Although previous
observations have suggested an increased risk of acute
rejection [71] and controversial effects on GFR [72, 73],
none of the randomized controlled trials have demonstrated
an increased incidence of acute rejection or a change in
GFR. However, two of them found that a history of two or
more acute rejection episodes before the initiation of rhGH
was predictive of a subsequent rejection episode following
the initiation of rhGH therapy [69, 70]. More recently, a
non-randomized study from the NAPRTCS compared 513
rhGH-treated transplant recipients to 2263 untreated chil-
dren over a 5-year period [74]. The authors concluded that
children younger than 10 years of age grew better than
older ones; the final height was superior in the rhGH-
treated group (mean cumulative increase of 3.6 cm),
without any significant change in allograft function and
graft failure rate, and the incidence of adverse events was
similar in both groups.
The immune system may be adversely affected by the
GH-induced stimulation of cytotoxic T cells in vitro [75].
However, data in pediatric renal transplant recipients
suggest either a transient or a moderate impact of rhGH
on the immune system [76, 77].
A major concern with the use of rhGH is the potential
risk of malignancy. There is no evidence of increased risk
of lymphoproliferative disease with the use of rhGH post-
transplant only. However, a significant association has been
found between the use of rhGH during the pre-transplant
period and the development of post-transplant lymphopro-
Table 2 Conservative methods to optimize growth velocity post-
transplantation [1, 87]
Causes of growth
impairment
Methods
Reduced GFR Prevention and management of chronic
allograft nephropathy
Treatment of acute rejection episodes
Drug compliance
Steroid therapy Daily low or alternate day steroid therapy
Steroid avoidance/withdrawal under evaluation
Bone disease Target PTH within normal range in CKD stage
2–3 and < 2× upper limit in CKD stage 4
Target plasma phosphate within age-appropriate
normal range
Metabolic acidosis Target plasma bicarbonate > 22 mmol/L
Malnutrition Adequate nutritional intake
Comorbidities Assessment and control of comorbidities which
may impair growth (chronic inflammation,
liver, lung or heart diseases)
PTH Parathyroid hormone; CKD chronic kidney disease
Pediatr Nephrol (2009) 24:1297–1306 1301liferative disease [78]. Tydén et al. reported the develop-
ment of renal cancer in the transplant kidneys of two
adolescents treated with rhGH [79]. However, an analysis
of data from companies commercializing rhGH was unable
to identify rhGH as a risk factor for post-transplant renal
cancer [80].
Other side effects have been reported under rhGH
therapy, but they do not represent a significant risk and
should not limit the current use of rhGH in growth-retarded
transplanted children. Several studies have shown a
transient elevation of glucose and insulin secretion in
rhGH-treated patients with CRI or after renal transplanta-
tion [81]. There has been no report of diabetes mellitus
development under rhGH, but one patient with cystinosis
has been reported. Recombinant human growth hormone
has also been found to induce an increase in lipoprotein(a)
serum concentration without a significant change in
cholesterol or triglycerides serum concentrations [82]. This
increase did not persist over time after a long-lasting
treatment with rhGH in patients with Turner syndrome
[83]. Transient increases in alkaline phosphatase activity,
serum phosphate concentration [70] or even PTH concen-
tration [68] have been observed in randomized controlled
trials, but rhGH did not induce an increased incidence of
renal osteodystrophy; however, overt renal osteodystrophy
may blunt the response to rhGH [84].
In a retrospective survey, benign intracranial hyperten-
sion was detected in about 1% of 1670 children with CRI
[85]. This complication may be exacerbated by the presence
of fluid overload and arterial hypertension associated with
CRI.
Current recommendations
The use of rhGH in growth-retarded renal transplant
recipients has not been approved by North American or
European drug regulatory agencies, so that there are no
clear guidelines for its use in such patients. In addition, the
American Association of Clinical Endocrinologists does not
recommend the use of rhGH after renal transplantation,
unless it is given as a part of a research study [86].
However, based on published trials and registries, a recent
report from the Kidney Foundation on Kidney Disease
Improving Global Outcomes (KDIGO) has provided rec-
ommendations for its use after pediatric renal transplanta-
tion [1]. All growth parameters should be assessed and
corrected before rhGH is initiated. Therapy with RhGH
can be started when height falls below the third centile for
age and sex. It remains uncertain whether GH therapy
should be considered in children with still-normal relative
height but low growth velocity. The recommended dose is
0.05 mg/kg per day (1.4 mg/m
2 per day) in prepubertal
children. In pediatric transplant patients with chronic
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1302 Pediatr Nephrol (2009) 24:1297–1306kidney disease stages 2–4, bone disease should be managed
according to K/DOQI guidelines [87]. A practical approach
for the use of rhGH after transplantation is proposed in
Table 4.
In summary, steroid-sparing/avoidance may be the first-
line management of short transplant children with a good
GFR (i.e. > 60 mL/min per 1.73 m
2), whereas rhGH
treatment may be proposed to those short patients with
either impaired GFR (i.e. <60 mL/min per 1.73 m
2) or the
failure of steroid-sparing/avoidance despite a good GFR.
Conclusion
Optimal growth is a major issue regarding post-transplan-
tation quality of life and self esteem in children. The current
final height of transplant patients has remained suboptimal,
but recent strategies, including steroid-sparing/avoidance
regimes, could further improve longitudinal growth in renal
transplant children.
Questions
(Answers appear following the reference list)
1) What has been learned from epidemiological data about
post-transplant growth?
a. Most renal transplant children attain target height
b. Growth velocity increases after 3 years post-
transplantation
c. Height SDS at transplantation has improved over
time
d. Catch-up growth is primarily exhibited by adoles-
cents
e. Quality of life of transplant recipients is not
influenced by height
2) Which factor positively influences growth post-trans-
plantation?
a. Male gender
b. Young age at transplantation
c. Primary tubular disorder
d. Prolonged steroid therapy
e. Dialysis prior to transplantation
3) Which mechanism contributes to glucocorticoids-
induced growth retardation?
a. Decreased serum IGF-1 concentration
b. Reduced sensitivity to endogenous GH and IGF-1
c. Direct stimulation of chondrocytes proliferation
d. Decreased production of all IGFBPs
e. Disturbances in the gonadotropic hormone axis
4) How can growth potential be optimized?
a. Correction of metabolic acidosis
b. Adequate nutritional intake
c. Prevention of bone disease
d. Supraphysiological dose of rhGH when indicated
e. All of the above
5) Which of the following statements about the use of
rhGH is correct?
a. The optimal dosage of rhGH is 0.02 mg/kg per day
b. There is evidence that rhGH improves final height
c. Randomized controlled trials with rhGH have
shown an increased risk of acute rejection
Table 4 Proposed recommendations for the use of rhGH in children
with a renal transplant
Recombinant human growth
hormone therapy
Factors to take into
consideration
Target population
for rhGH therapy
Prepubertal children
Pubertal children?
−2 SDS for height
Poor growth velocity?
Growth potential documented
by open epiphyses
Correction of other factors
contributing to growth failure
Contra-indication Active malignancy
Baseline evaluation Pubertal stage
Anthropometric assessment
Target height
Hip X-ray and bone age
Fundoscopic examination
Serum phosphate, calcium and PTH
Optimal dose of rhGH 0.05 mg/kg per day (4 IU/m
2 per day)
Mode of administration Daily subcutaneous injection
Follow-up evaluation Height, weight, growth velocity every
3 months
Close monitoring of graft function in
children with a history of acute
rejection
Serum calcium, phosphate and PTH
every 3 months
Bone age every year according
to growth profile
rhGH discontinuation Achieved height endpoint
Closed epiphyses
Slipped femoral epiphyses
Severe hyperparathyroidism
Active malignancy
Documented benign intracranial
hypertension
Non compliance
Pediatr Nephrol (2009) 24:1297–1306 1303d. rhGH may induce an elevation of serum insulin
concentration
e. rhGH has been identified as a risk factor for post
transplantation malignancy
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